India's
pharmaceutical market is a vast marketplace with an yearly turnover
crossing Rs. 800 Billion (US$ 12.3 Billion) with thousands of Pharma
manufacturers competing with each other offering a plethora of drugs.
Last year ( 2013-14) the single largest selling class of drugs were
the formulations based on Amoxicillin- that comes from the class of
antibiotics known as Penicillins. This drug fights bacteria in the
body and is widely used to treat many different infections caused by
bacteria, such as sinusitis, pneumonia, ear infections, bronchitis,
urinary tract infections, and infections of the skin. During last
12-month period ending in May 2014, just one popular formulation
consisting of Amoxycillin, had crossed a sales figure of Rs 13.36
billion in sales. This is obviously as it should be, because this
formulation is used to treat the most common ailments that affect the
people.
The
second best selling formulation sold in this marketplace last year
was an anti-diabetic drug—a combination of two molecules,
Glimepiride and Metformin, that is used to treat diabetes. In India,
this combination is most commonly-used since it is cheap and
effective. The retail sales figures for this formulation has been
calculated as Rs 11.42 Billion. This however is a great cause of
concern as it indicates the unprecedented rise of Diabetes in India.
As per
the International Diabetes Federation, India is the diabetes capital
of the world, with 40 million people living with diabetes with proper
medicare. About 371 million people suffer from diabetes across the
nation and half of the cases are undiagnosed. In the Indian state of
Maharashtra, where I live, blood sugar levels are found to be high,
surprisingly among youth, especially in the the age group of 25-35
years of age. Younger women in the age bracket of 30-35 years are
found to be prone to diabetes because of sedentary lifestyle and
wrong eating habits. A study conducted recently has found that that
excessive consumption of oil, ghee,butter and cholesterol rich diet
increases obesity and hypertension, which fuels chances of getting
diabetes. By 2030, India will have the largest number of patients in
the world. Diabetes is not only a blood sugar problem, but brings
along other complications as well. Diabetes takes a severe toll on
the heart too. The incidence of heart disease in India is increasing
at a rapid rate. It was 1.09% in the 1950s, increased to 9.7 % in
1990, and 11% by year 2000.
The
statistics from India are quite scary but when we consider the world
and in particular the developing world, the picture becomes even more
deadly. According to latest estimates diabetes Kills one person every
six seconds and afflicts 382 million people around the world. By
2035, The number of people affected by the disease is expected to
climb 55 percent to 592 million. 5.1 million people die annually
because of the disease, with an average 10 million diabetes cases
emerging every year. Every year, diabetes also leads to more than 1
million amputations, 500,000 kidney failures and 1.5 million cases of
blindness.
Unfortunately,
Four of every five people with diabetes are living in developing
countries where they have fewer resources at hand to fight the
disease. A report published in September 4 issue of, 'Journal of the
American Medical Association' says that in China, recent figures
showed that the epidemic being much worse than previously estimated.
A study has found out that 12 percent of adults, or 114 million
people, have the disease. 22 million diabetics, equivalent to the
population of Australia, are added every year. That means that almost
one in three diabetes sufferers globally, is in China.
This
is indeed a scary picture. Yet the latest news from the market is
even more scary. In the month of May 2014, out of the total
Pharmaceutical sector retail sales of Rs. 66 Billion, anti Diabetic
formulations consisting of Glimepiride plus Metformin have surpassed
the total sales figure of anti-infective formulations based on
Amoxicilline. Anti Diabetic formulations sales have been clocked at
of Rs 1.05 Billion against the anti-infective therapy sales of Rs
1.03 Billion.
According
to the analysts, this is really disturbing because anti-infective
therapy had always been ranked on top before. There is another minor
reason for decline in growth rate of anti infection drugs. It was
brought under under price control regime by the Government. This must
have had some effect because effective price of these formulations
has come down by 9% in last year ending May 2014. However, this can
not the principal reason for the comparative decline, because
Amoxicilline sales volumes have been growing around 7% in the same
period.
The
primary reason for the anti-diabetic formulation taking the lead is
obviously because it is being prescribed more and more, which in
other words means that the spectre of Diabetes is catching up with
more and more Indians ever than before. In fact this anti Diabetic
formulation sales have actually grown by a staggering rate of 34.4%
in May 2014.
There
is no denying that diabetes is a genetic disease and if one of your
parent (particularly your mother) had it, the chances of your getting
it are quite high. Still it remains very clear that the cornerstone
of prevention or at least control of diabetes is regular exercise,
managing stress and healthy food habits. And if one of your parents
had it, then you should be even more concerned or cautious about it.
The unprecedented rise of diabetes is a biggest cause of concern for
all Indians and all of us must look at the lifestyle changes as a
necessity.
19th
June 2014
No comments:
Post a Comment